Hire an Advanced Robo-Advisor to Trade BMRN on Your Behalf.

Stock Detail Header
  • Street Sentiment
  • Personalized Strategy
  • Free Trading Simulator
Get Started
Stock Details
  • PRICE$82.57
  • PRICE CHANGE$0.01
  • % CHANGE0.01%
  • TWEETS15
  • CONSENSUSSELL

Trends

Course of Action

SELL

Sentiment (10 days)

  •  Strong Buy
  •  Buy
  •  Hold
  •  Sell
  •  Strong Sell

DAILY PRICE CHANGE VS SENTIMENT

  • BullishBullish
  • BearishBearish
  • SentimentSentiment
  • BarPrice

Why Invest Using a Robo-Advisor?

Smart Auto-Trading is an advanced robo-advisor designed to automate securities investing. Its robo is designed to screens, monitors and auto-trades elite stocks like BIOMARIN PHARMACEUTICAL INC (BMRN) using artificial intelligence, social media and market data. Using Smart Auto-Trading in your brokerage account holds the potential to accelerate your financial performance.

Recommended Usage

Converting your 401k to a Rollover IRA and auto-trade in it using Smart Auto-Trading from Stock Circles could be a great strategy to grow your retirement account while you work. Smart Auto-Trading is an actively trading robo-advisor that auto-trades the S&P 500 on your behalf.

Based on historical performance, Smart Auto-Trading's model strategies have displayed the potential to increase yield and grow retirement accounts quicker than if you were to use a passive investment method using the same securities. Active trading is a systematic investment strategy that uses price momentum, short-term trades and compounding to build wealth.

In the past 2 years, the system has produced great results. Smart Auto-Trading makes short-term trades. If these trades happen in a tax-deferred account, you do not get taxed until you start taking money out of the account. So if you start auto-trading today in your retirement account and auto-trade for 10, 20, 30 years, imagine how much money this automated strategy as the potential to create for you.

This investment system works great for tax-deferred accounts like Keogh, SIMPLE IRA, traditional IRA, IRA, Rollover IRA, 529 College plans and UGMA and you can trade with a minimum of $5,000 in your account.

Smart Auto-Trading is very affordable. You will pay a low monthly fee to use it. Using Smart Auto-Trading will usually pay for itself on the first successful trade of the month.

Robo investing is super easy

Robo-investing with Smart Auto-Trading is easy. You do not need to know anything about stock investing. All you need to do is to setup your trading strategy and the trading robot will take care of the rest. Stock Circles offers a default strategy to help you get started. You can test the strategy in simulation mode free of charge today. Once comfortable with the outcome, you are ready to trade real money. You can then connect Smart Auto-Trading to your brokerage account and start to auto-trade.

Past performance does not guarantee future success. Smart Auto-Trading will do its best to take advantage of the market but if the market goes down for a long period of time then there is no money to be made than everyone is affected. Robo-Advisors like Smart Auto-Trading are good at what they do but they don’t have super powers.

Smart Auto-Trading trades only elite stocks. By trading the S&P 500, Nasdaq 100 and Dow 30, Smart Auto-Trading uses widely traded stocks.

Smart Auto-Trading uses Artificial Intelligence concepts to screen, monitor and auto-trade stocks. It monitors and trades on your behalf while you attend more important life events.

Take advantage of active trading today by registering at stockcircles.com It's free to start in simulation mode.

Benefits

There are clear benefits associated with using a robo-advisor such as Smart Auto-Trading to help you reach your financial goals. Smart Auto-Trading simplifies stock investing down to a few steps. It auto-trades for you, using your personalized strategy, while you attend more important life events.

Using Smart Auto-Trading is like having thousands of traders working for you to help you reach your financial goals.

Smart Auto-Trading actively trades which is different from passive investing. The robo is on the lookout working to maximize your potential every business day of the year. It trades on the news taking advantage of price changes and trends by listening into trader's communications and by validating this information with market data.

Smart Auto-Trading is one of the first robo-advisor to take advantage of Government grade listening technology, artificial intelligence, social media and market data natively.

Try Smart Auto-Trading today!

You can test Smart Auto-Trading in simulation mode, risk free, Stock Circles today.

Get started now - and see where active automated trading can take you.

Disclaimer: Past performance may not be indicative of future results. Therefore, you should assume that the future performance of any specific investment, investment strategy (including robo-strategies), or product made in reference directly or indirectly on this website, will be profitable or equal to corresponding indicated performance levels. Robot-Advisors like other investment methods rely on favorable market conditions to provide positive outcomes.

BIOMARIN PHARMACEUTICAL INC (BMRN) News

BioMarin Pharmaceutical Inc. (BMRN) Given Buy Rating at BMO Capital Markets

BMO Capital Markets restated their buy rating on shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in a research note published on Friday, September 15th.

A number of other equities research analysts also recently issued reports on BMRN. Deutsche Bank AG reissued a buy rating and set a $119.00 price target (up previously from $118.00) on shares of BioMarin Pharmaceutical in a research report on Wednesday, August 9th. Wedbush restated a neutral rating and issued a $108.00 price target on shares of BioMarin Pharmaceutical in a research report on Monday, August 7th. UBS AG reaffirmed a neutral rating and set a $93.00 price objective (up previously from $92.00) on shares of BioMarin Pharmaceutical in a research report on Thursday, August 3rd. Cowen and Company restated a buy rating on shares of BioMarin Pharmaceutical in a research report on Friday, August 4th. Finally, Stifel Nicolaus reiterated a buy rating and issued a $107.00 price target on shares of BioMarin Pharmaceutical in a research note on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $109.09.

Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) opened at 93.73 on Friday. The stock has a 50 day moving average of $88.49 and a 200 day moving average of $89.61. The company’s market cap is $16.43 billion. BioMarin Pharmaceutical has a 52-week low of $78.42 and a 52-week high of $100.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.01. BioMarin Pharmaceutical had a negative return on equity of 5.77% and a negative net margin of 15.54%. The company had revenue of $317.50 million for the quarter, compared to the consensus estimate of $311.41 million. During the same quarter in the prior year, the business earned ($2.61) earnings per share. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. On average, equities analysts anticipate that BioMarin Pharmaceutical will post ($0.71) earnings per share for the current fiscal year.

In other news, Director V Bryan Lawlis sold 3,750 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $91.26, for a total value of $342,225.00. Following the transaction, the director now owns 19,660 shares in the company, valued at $1,794,171.60. Also, insider Henry J. Fuchs sold 15,000 shares of the stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $90.50, for a total transaction of $1,357,500.00. Following the sale, the insider now owns 141,422 shares of the company’s stock, valued at $12,798,691. The disclosure for this sale can be found here. Insiders have sold a total of 40,686 shares of company stock worth $3,736,318 over the last quarter. Corporate insiders own 1.85% of the company’s stock.

A number of institutional investors have recently modified their holdings of BMRN. Cigna Investments Inc. New lifted its position in shares of BioMarin Pharmaceutical by 1.5% in the 2nd quarter. Cigna Investments Inc. New now owns 2,377 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 36 shares during the period. Daiwa Securities Group Inc. grew its holdings in shares of BioMarin Pharmaceutical by 1.0% during the 2nd quarter. Daiwa Securities Group Inc. now owns 4,950 shares of the biotechnology company’s stock worth $450,000 after acquiring an additional 50 shares during the period. Ameritas Investment Partners Inc. grew its stake in BioMarin Pharmaceutical by 1.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,126 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 54 shares during the period. NGAM Advisors L.P. raised its holdings in BioMarin Pharmaceutical by 0.4% in the second quarter. NGAM Advisors L.P. now owns 15,245 shares of the biotechnology company’s stock worth $1,385,000 after purchasing an additional 55 shares in the last quarter. Finally, First American Trust FSB raised its holdings in BioMarin Pharmaceutical by 0.3% in the second quarter. First American Trust FSB now owns 26,696 shares of the biotechnology company’s stock worth $2,424,000 after purchasing an additional 73 shares in the last quarter. 97.47% of the stock is currently owned by institutional investors and hedge funds.

Get Started today! - Risk Free

Investors who like BIOMARIN PHARMACEUTICAL INC (BMRN) also like

Most Talked About Stocks on Stock Circles

Stock Bubbles